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To determine trends, mortality rates, and costs of antimi-
crobial resistance in invasive bacterial infections in hospi-
talized children, we analyzed data from Angkor Hospital 
for Children, Siem Reap, Cambodia, for 2007–2016. A 
total of 39,050 cultures yielded 1,341 target pathogens. 
Resistance rates were high; 82% each of Escherichia coli 
and Klebsiella pneumoniae isolates were multidrug resis-
tant. Hospital-acquired isolates were more often resistant 
than community-acquired isolates; resistance trends over 
time were heterogeneous. K. pneumoniae isolates from 
neonates were more likely than those from nonneonates 
to be resistant to ampicillin–gentamicin and third-genera-
tion cephalosporins. In patients with community-acquired 
gram-negative bacteremia, third-generation cephalosporin 
resistance was associated with increased mortality rates, 
increased intensive care unit admissions, and 2.26-fold 
increased healthcare costs among survivors. High anti-
microbial resistance in this setting is a threat to human 
life and the economy. In similar low-resource settings, our 
methods could be reproduced as a robust surveillance 
model for antimicrobial resistance.
Worldwide, invasive bacterial infections are a lead-ing cause of childhood deaths, mostly in low- 
and middle-income countries (1). Management of such 
infections is threatened by the rising prevalence of anti-
microbial resistance (AMR), particularly among neonates 
(2). However, data on AMR in invasive bacterial infec-
tions in children from low- and middle-income countries 
are scarce (3–6).
To combat the global threat of AMR, improved sur-
veillance to detect emerging and long-term resistance 
trends is vital (7). Several global initiatives, such as the 
Fleming Fund, have been recently established to improve 
laboratory capacity in low- and middle-income countries 
(7,8), and the World Health Organization (WHO) Global 
Antimicrobial Resistance Surveillance System (GLASS) 
(9) has targeted 6 invasive pathogens for routine antimi-
crobial resistance surveillance: Escherichia coli, Klebsiella 
pneumoniae, Acinetobacter baumannii, Salmonella spp., 
Staphylococcus aureus, and Streptococcus pneumoniae. 
Monitoring resistance in these pathogens is particularly 
important for invasive bacterial infections in children in 
low- and middle-income countries, where most treatment is 
empirically prescribed and must be based on reliable con-
temporaneous resistance data to be effective.
Recent systematic reviews of AMR in invasive bac-
terial infections in children highlight the paucity of data 
available and do not report temporal resistance trends (5,6). 
In addition, although recent studies indicate excess deaths 
caused by AMR in low- and middle-income countries (10), 
there is limited evidence describing the economic and mor-
tality burden of resistance at the patient level, particularly 
among children.
We analyzed 10 years of continuous AMR surveil-
lance data for invasive bacterial infections in children from 
a sentinel surveillance site in Cambodia and describe re-
sistance trends over time, by age group, and by site of ac-
quisition (community or hospital). To evaluate the excess 
deaths and cost burden associated with third-generation 
cephalosporin resistance in community-acquired gram-
negative bacteremia in hospitalized children, we analyzed 
patient-level data.
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Study Design and Sample Selection
Angkor Hospital for Children is an ≈100-bed nongov-
ernmental hospital in Siem Reap, Cambodia. Of children 
admitted, around two thirds reside in Siem Reap Prov-
ince (11), where the incidence of poverty exceeds 50% 
(12); 93% are admitted from the community and 7% are 
transferred from another hospital (P. Turner, unpub data). 
Because this hospital has no maternity/obstetric ward, all 
children are born outside the hospital. Blood cultures are 
routinely taken from febrile (axillary temperature >37.5°C) 
hospitalized patients, according to clinical algorithms, at no 
patient cost. 
We reviewed hospital microbiology data for 2007–
2016 and extracted AMR data for selected blood culture 
and cerebrospinal fluid (CSF) culture isolates. Target or-
ganisms consisted of the 6 GLASS blood culture priority 
pathogens (9), Neisseria meningitidis (a vaccine-prevent-
able pathogen), and non-GLASS pathogens for which >30 
organisms were isolated over the study period. We includ-
ed in the study the first isolate of a given organism per pa-
tient per 14-day infection episode, except for Salmonella 
spp., for which we included only the first isolate per patient 
to avoid double counting potential relapses. Clinical data 
were extracted from hospital patient records. The study was 
approved by the Angkor Hospital for Children Institutional 
Review Board (AHC-IRB, 0185-17) and the Oxford Tropi-
cal Research Ethics Committee (OxTREC, 508-17).
Procedures and AMR Reporting
We processed blood and CSF culture specimens as de-
scribed elsewhere (11,13). Antimicrobial susceptibility 
testing was undertaken by disk diffusion and Etest MIC, 
according to Clinical and Laboratory Standards Institute 
guidelines (14) (online Technical Appendix Methods and 
Table 1, https://wwwnc.cdc.gov/EID/article/24/5/17-1830-
Techapp1.pdf). Resistance proportions are reported as 
number of resistant isolates/number of isolates tested.
Outcome Analyses
We included in patient outcome analyses community-ac-
quired monomicrobial Enterobacteriaceae (excluding Sal-
monellae) and A. baumannii bacteremia. These pathogens 
represent common causes of sepsis in children worldwide 
where third-generation cephalosporins would be a first-
line/empiric treatment. We obtained clinical and costing 
data from hospital records and calculated cost per patient 
as admission cost plus antimicrobial costs.
Statistical Analyses
We treated isolates from specimens taken within 48 hours 
of admission as community-acquired infections and 
after 48 hours as hospital-acquired infections. However, 
Salmonella enterica serotypes Typhi and Paratyphi and 
Burkholderia pseudomallei isolates were always consid-
ered community-acquired infections. To ensure sufficient 
data per period, we grouped isolates into 2-year blocks. We 
assessed associations between resistance and year of isola-
tion, patient age group, and site of acquisition (community 
vs. hospital) by univariable and multivariable logistic re-
gression. Multivariable models included all variables. Ac-
cording to assessment of model fit by calculation of Akaike 
information criterion and plotting of observed versus pre-
dicted data, we considered time (year of isolation) a factor 
unless otherwise stated.
For the outcome analyses, we used univariable anal-
ysis to compare variables by third-generation cephalo-
sporin resistance status and patient outcome by using the 
Mann-Whitney-Wilcoxon rank-sum test for continuous 
variables and the χ2 test with Yates correction for cat-
egorical variables. For multivariable logistic regression, 
outcome variables were hospital deaths and intensive 
care unit (ICU) admissions, and covariates were resis-
tance, age group, age <10 years, malnutrition, sex, and 
organism type (Enterobacteriaceae vs. A. baumannii). 
We conducted multivariable linear regression by using 
admission duration and cost for survivors as outcome 
variables and using the same covariates. The linear 
model variables were log transformed, and results are 
presented with log- and back-transformed coefficients, 
which is interpreted as a multiplicative rather than an 
additive model. Analyses were undertaken by using the 
R statistical package (15).
Results
During the 10-year study period, 39,050 sterile site samples 
were collected for culture: 36,358 (93.1%) blood and 2,692 
(6.9%) CSF (online Technical Appendix Figure 1). The 
sampling rate, indicated by the blood culture:hospital ad-
mission ratio, rose throughout the study period as utility of 
the clinical microbiology service increased. Approximately 
1 blood culture was sent for every 3 admissions in 2007 
(1,293 blood cultures:3,829 admissions), rising to 1 blood 
culture per admission in 2013 (5,294 blood cultures:5,208 
admissions) and subsequently remaining stable (online 
Technical Appendix Figure 2). From 2012 through 2016, 
the proportion of blood cultures from neonates rose from 
9.1% to 21.2%, and the proportion from children >5 years 
of age dropped from 35.4% to 22.4% (online Technical Ap-
pendix Table 2).
Of the 39,050 specimens collected, 3,666 (9.4%) were 
culture positive, yielding 4,028 isolates. Skin organism con-
tamination was identified in 1,937 (5.3%) blood cultures. 
Clearly pathogenic bacteria comprised 37.5% (1,512) of 
isolates grown, 9.1% (366) were of uncertain significance, 
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and 53.4% (2,150) were designated skin contaminants. A 
total of 1,341 target organisms met inclusion criteria; 1,088 
(81.1%) were GLASS pathogens and 253 (18.9%) were 
non-GLASS pathogens. GLASS pathogens were Salmo-
nella spp. (408, 30.4%); S. aureus (186, 13.9%); S. pneu-
moniae (166, 12.4%); K. pneumoniae (146, 10.9%); E. coli 
(107, 8.0%); and A. baumannii (75, 5.6%).
Overall AMR Rates 
Overall AMR rates were high, especially among gram-
negative GLASS organisms (Table 1). Ampicillin–genta-
micin resistance (resistance to both agents) was detected 
in 62.1% (90/145) of K. pneumoniae isolates and 47.2% 
(50/106) of E. coli isolates. Third-generation cephalo-
sporin resistance was detected in 78.8% (115/146) of 
K. pneumoniae isolates, 49.5% (53/107) of E. coli iso-
lates, and 93.3% (70/75) of A. baumannii isolates; multi-
drug resistance in these 3 organisms was 81.8% (108/132), 
82.1% (69/84), and 93.3% (70/75), respectively. Carbape-
nem resistance was uncommon: <1% of K. pneumoniae 
(1/142) and E. coli isolates (0/98) and 13.5% (10/74) of 
A. baumannii isolates were resistant.
Resistance differed greatly among the 3 groups of 
Salmonella spp. The proportion of resistant isolates was 
highest for Salmonella Typhi: 95.7% (308/322) were 
fluoroquinolone resistant, 86.0% (270/314) multidrug re-
sistant, and 85.0% (266/313) fluoroquinolone and multi-
drug resistant. The least resistant group was Salmonella 
Paratyphi A: 22.7% (10/44) of isolates were fluoroquino-
lone resistant and none were multidrug resistant (0/43). 
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Table 1. Resistance proportions by year of isolation for the 1,088 Global Antimicrobial Resistance Surveillance System pathogens 
isolated from children at Angkor Hospital for Children, Siem Reap, Cambodia, 2007–2016* 
Pathogen, resistance type 
No. isolates  
resistant/no. tested (%) 
Year of isolation 
2007–2008 2009–2010 2011–2012 2013–2014 2015–2016 
Gram-negative       
 Klebsiella pneumoniae 146 11 17 56 42 20 
  AMP–GEN† 90/145 (62.1) 5/11 (45.5) 10/16 (62.5) 46/56 (82.1) 26/42 (61.9) 3/20 (15.0) 
  3GC 115/146 (78.8) 8/11 (72.7) 13/17 (76.5) 50/56 (89.3) 37/42 (88.1) 7/20 (35.0) 
  Carbapenem 1/142 (0.7) 0/8 0/16 0/56 1/42 (2.4) 0/20 
  Multidrug 108/132 (81.8) 8/8 (100) 12/12 (100) 45/50 (90.0) 36/42 (85.7) 7/20 (35.0) 
 Escherichia coli 107 12 22 21 30 22 
  AMP–GEN 50/106 (47.2) 4/12 (33.3) 12/21 (57.1) 8/21 (38.1) 17/30 (56.7) 9/22 (40.9) 
 AMP 101/107 (94.4) 10/12 (83.3) 21/22 (95.5) 21/21 (100) 28/30 (93.3) 21/22 (95.5) 
 GEN 51/106 (48.1) 4/12 (33.3) 12/21 (57.1) 8/21 (38.1) 18/30 (60.0) 9/22 (40.9) 
  3GC 53/107 (49.5) 3/12 (25.0) 11/22 (50.0) 11/21 (52.4) 16/30 (53.3) 12/22 (54.5) 
   Carbapenem 0/98 0/3 0/22 0/21 0/30 0/22 
  Multidrug  69/84 (82.1) 3/3 (100) 13/13 (100) 15/16 (93.8) 23/30 (76.7) 15/22 (68.2) 
 Acinetobacter baumannii 75 2 7 30 27 9 
  3GC 70/75 (93.3) 2/2 (100) 6/7 (85.7) 27/30 (90.0) 27/27 (100) 8/9 (88.9) 
  Carbapenem 10/74 (13.5) 1/2 (50.0) 1/6 (16.7) 5/30 (16.7) 3/27 (11.1) 0/9 
  Multidrug  21/71 (29.6) 1/2 (50.0) 2/6 (33.3) 9/27 (33.3) 8/27 (29.6) 1/9 (11.1) 
 Salmonella Typhi 323 44 51 146 40 42 
  FQ 308/322 (95.7) 39/44 (88.6) 48/51 (94.1) 139/145 (95.9) 40/40 (100) 42/42 (100) 
  CRO 1/173 (0.6) 0/44 1/21 (4.8) 0/26 0/40 0/42 
  MDR 270/314 (86.0) 31/41 (75.6) 39/47 (83.0) 134/144 (93.1) 35/40 (87.5) 31/42 (73.8) 
  FQ and multidrug 266/313 (85.0) 30/41 (73.2) 38/47 (80.9) 132/143 (92.3) 35/40 (87.5) 31/42 (73.8) 
 Salmonella Paratyphi A 44 3 0 0 35 6 
  FQ 10/44 (22.7) 3/3 (100) 
  
4/35 (11.4) 3/6 (50.0) 
  CRO 0/44 0/3   0/35 0/6 
  MDR 0/43 0/2 
  
0/35 0/6 
  FQ and multidrug 0/0 0/0   0/0 0/0 
 Non-Typhoid Salmonellae 41 7 4 7 9 14 
  FQ 26/41 (63.4) 4/7 (57.1) 2/4 (50.0) 4/7 (57.1) 6/9 (66.7) 10/14 (71.4) 
  CRO 3/37 (8.1) 0/7 0/4 1/3 (33.3) 0/9 2/14 (14.3) 
  Multidrug 9/39 (23.1) 3/7 (42.9) 1/2 (50.0) 2/7 (28.6) 2/9 (22.2) 1/14 (7.1) 
  FQ and multidrug 5/39 (12.8) 3/7 (42.9) 1/2 (50.0) 0/7 0/9 1/14 (7.1) 
Gram-positive       
 Staphylococcus aureus 186 26 38 43 42 37 
  MET 24/185 (13.0) 3/26 (11.5) 4/38 (10.5) 8/42 (19.0) 3/42 (7.1) 6/37 (16.2) 
  VAN 0/9 0/0 0/0 0/0 0/3 0/6 
 Streptococcus pneumoniae 166 17 36 40 41 32 
  Penicillin 73/144 (50.7) 5/9 (55.6) 10/23 (43.5) 16/39 (41.0) 20/41 (48.8) 22/32 (68.8) 
  MAC/LIN 49/165 (29.7) 5/17 (29.4) 10/35 (28.6) 12/40 (30.0) 11/41 (26.8) 11/32 (34.4) 
  MDR 63/93 (67.7) 0/0 0/0 10/20 (50.0) 26/41 (63.4) 27/32 (84.4) 
*Resistance proportions are reported as no. resistant isolates/no. isolates tested. Blank cells indicate that no organisms were tested during that period and, 
thus, the proportion of resistant organisms is unknown. 3GC, third-generation cephalosporin; AMP–GEN, resistance to both ampicillin and gentamicin; CRO, 
ceftriaxone; FQ, fluoroquinolone; MDR, multidrug resistant; MAC/LIN, resistance to macrolides and/or lincosamides; MET, methicillin; VAN, vancomycin.  
†K. pneumoniae is intrinsically resistant to AMP, and thus AMP–GEN resistance in K. pneumoniae isolates is equivalent to GEN resistance. 
 
SYNOPSIS
Resistance in nontyphoidal Salmonella spp. fell between 
that of Salmonella Typhi and Paratyphi A: 63.4% (26/41) 
of isolates were fluoroquinolone resistant, 23.1% (9/39) 
multidrug resistant, and 12.8% (5/39) fluoroquinolone and 
multidrug resistant. Only 1.6% (4/254) of Salmonella spp. 
isolates were ceftriaxone resistant.
In gram-positive GLASS organisms, approximately 
one third of S. pneumoniae isolates were macrolide/lin-
cosamide resistant (29.7%, 49/165), half were penicillin 
resistant (50.7%, 73/144), and two thirds were multidrug 
resistant (67.8%, 63/93). Only 13.0% (24/185) of S. aureus 
isolates were methicillin resistant.
The most frequently isolated non-GLASS pathogen 
was Burkholderia pseudomallei, the causative agent of 
melioidosis (26.1%, 66), which was universally sensitive 
to the first-line drugs ceftazidime and co-trimoxazole 
(Table 2). Next was Haemophilus influenzae, for which 
approximately half of isolates were ampicillin resistant 
(53.6%, 30/56) and one third multidrug resistant (37.1%, 
13/35), followed by Enterobacter cloacae, which had a 
similar resistance profile to K. pneumoniae and E. coli. 
The remaining non-GLASS pathogens (group A Strep-
tococcus, Pseudomonas aeruginosa, and Neisseria men-
ingitides) exhibited low-level resistance to the key anti-
microbials reported.
AMR Time Trends 
The most frequently isolated organisms were K. pneu-
moniae, E. coli, Salmonella Typhi, S. aureus, and S. 
pneumoniae; AMR time trends were heterogeneous (Ta-
bles 1, 3–5; Figure 1). S. pneumoniae penicillin resistance 
fluctuated over time; 55.6% (5/9) of isolates were resistant 
in 2007–2008, dropping to 41.0% (16/39) in 2011–2012 
before rising to 68.8% (22/32) in 2015–2016. During 
2011–2016, when we tested S. pneumoniae for multi-
drug resistance, the proportion of multidrug-resistant S. 
pneumoniae isolates increased from 50.0% to 84.4%. Sal-
monella Typhi fluoroquinolone resistance also increased 
over the study period, from 88.6% to 100%. Multivariable 
logistic regression analysis in which time was a continu-
ous variable showed an increased probability of Salmo-
nella Typhi fluoroquinolone resistance over time (adjust-
ed odds ratio [aOR] 2.14, 95% CI 1.29–3.74; p = 0.005), 
although not statistically significant in the model when 
time was a factor (online Technical Appendix Table 3 and 
Figure 3). Conversely, during 2015–2016, the proportion 
of resistant K. pneumoniae isolates fell dramatically for 
most antimicrobials tested, a phenomenon not seen for E. 
coli (online Technical Appendix Table 4). For E. coli, am-
picillin–gentamicin and third-generation cephalosporin 
resistance remained stable at ≈50% with no evidence of 
significant change over time, as did rates of methicillin-
resistant S. aureus, which remained low throughout the 
study period. The proportion of K. pneumoniae isolates 
from neonates peaked in 2011–2014 at 46%–50% before 
dropping in 2015–2016 to 35% (online Technical Ap-
pendix Table 5), paralleling the change in the proportion 
of resistant isolates seen. To determine any subtle shifts 
in susceptibility, we examined changes in zone diameter 
distribution over time for E. coli and K. pneumoniae and 
found no clear trends (online Technical Appendix Table 
6, Figures 4, 5).
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Table 2. Resistance proportions by year of isolation for the 253 non-Global Antimicrobial Resistance Surveillance System pathogens 
isolated from children at Angkor Hospital for Children, Siem Reap, Cambodia, 2007–2016* 
Pathogen, resistance type 
No. isolates  
resistant/no. tested (%) 
Year of isolation 
2007–2008 2009–2010 2011–2012 2013–2014 2015–2016 
Burkholderia pseudomallei 66 6 10 13 22 15 
 CAZ 0/66 0/6 0/10 0/13 0/22 0/15 
 TMP/SXT 0/61 0/2 0/10 0/12 0/22 0/15 
Haemophilus influenzae 57 15 15 9 12 6 
 AMP 30/56 (53.6) 5/14 (35.7) 10/15 (66.7) 7/9 (77.8) 8/12 (66.7) 0/6 
 CRO 3/57 (5.3) 1/15 (6.7) 1/15 (6.7) 0/9 1/12 (8.3) 0/6 
 Multidrug 13/35 (37.1) 0/0 5/10 (50.0) 5/7 (71.4) 3/12 (25.0) 0/6 
Enterobacter cloacae 42 2 6 8 17 9 
 AMP֪–GEN 19/42 (45.2) 1/2 (50.0) 5/6 (83.3) 5/8 (62.5) 6/17 (35.3) 2/9 (22.2) 
 3GC 34/42 (81.0) 1/2 (50.0) 5/6 (83.3) 7/8 (87.5) 14/17 (82.4) 7/9 (77.8) 
 Carbapenem 3/41 (7.3) 0/1 0/6 0/8 2/17 (11.8) 1/9 (11.1) 
 Multidrug 18/37 (48.6) 1/1 (100) 2/2 (100) 5/8 (62.5) 7/17 (41.2) 3/9 (33.3) 
Group A Streptococcus 38 2 6 6 13 11 
 MAC/LIN 6/37 (16.2) 0/2 1/5 (20.0) 0/6 2/13 (15.4) 3/11 (27.3) 
Pseudomonas aeruginosa 37 7 6 7 9 8 
 CAZ 4/34 (11.8) 0/4 1/6 (16.7) 1/7 (14.3) 2/9 (22.2) 0/8 
 Carbapenem 2/30 (6.7) 0/1 0/5 1/7 (14.3) 0/9 1/8 (12.5) 
 Multidrug 0/29 0/0 0/5 0/7 0/9 0/8 
Neisseria meningitidis 13 6 3 0 2 2 
 CRO 1/13 (7.7) 0/6 1/3 (33.3) 
 
0/2 0/2 
*Resistance proportions have been reported as number of resistant isolates out of number of isolates tested. Blank cell indicates that no organisms were 
tested during that period and, thus, the proportion of resistant organisms is unknown. 3GC, third-generation cephalosporin; AMP–GEN, resistance to both 
ampicillin and gentamicin; CAZ, ceftazidime; CRO, ceftriaxone; MAC/LIN, resistance to macrolides and/or lincosamides; TMP/SXT, 
trimethoprim/sulfamethoxazole. 
 
 Antimicrobial Resistance in Bacterial Infections
AMR by Patient Age Group
Isolates from younger children were more often resistant 
to clinically important antimicrobials (Tables 3–5; Figure 
2; online Technical Appendix Tables 7–9). Multivariable 
logistic regression controlling for year of isolation and 
site of acquisition indicated that K. pneumoniae isolates 
from neonates were >7 times more likely to be resistant 
to the first-line treatment agents ampicillin–gentamicin 
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Table 3. Logistic regression analysis of resistance trends for the gram-negative Global Antimicrobial Resistance Surveillance System 
pathogens Klebsiella pneumoniae and Escherichia coli isolated from children at Angkor Hospital for Children, Siem Reap, Cambodia, 
2007–2016* 





OR (95% CI) p value OR (95% CI) p value 
Klebsiella pneumoniae      
 AMP–GEN      
  Year of isolation      
   2007–2008 Ref Ref  Ref Ref 
   2009–2010 2.00 (0.42–10.03) 0.384  1.31 (0.23–7.88) 0.765 
   2011–2012 5.52 (1.41–22.90) 0.015  2.61 (0.58–12.45) 0.213 
   2013–2014 1.95 (0.51–7.80) 0.329  0.59 (0.12–2.85) 0.504 
   2015–2016 0.21 (0.03–1.12) 0.075  0.06 (0.01–0.41) 0.006 
  Patient age      
   Nonneonate Ref Ref  Ref Ref 
   Neonate† 5.63 (2.61–13.10) <0.001  7.30 (2.75–22.47) <0.001 
  Infection type‡      
   Community-acquired Ref Ref  Ref Ref 
   Hospital-acquired 3.87 (1.81–8.51) <0.001  3.62 (1.42–9.58) 0.008 
 3GC      
  Year of isolation      
   2007–2008 Ref Ref  Ref Ref 
   2009–2010 1.22 (0.20–7.02) 0.823  0.87 (0.13–5.60) 0.881 
   2011–2012 3.13 (0.57–14.69 0.156  1.37 (0.23–7.16) 0.716 
   2013–2014 2.78 (0.49–13.93) 0.218  0.97 (0.15–5.58) 0.973 
   2015–2016 0.20 (0.03–0.94) 0.052  0.06 (0.01–0.39) 0.005 
  Patient age      
   Nonneonate Ref Ref  Ref Ref 
   Neonate 6.41 (2.32–22.70) 0.001  7.50 (2.16–35.00) 0.004 
  Infection type      
   Community-acquired Ref Ref  Ref Ref 
   Hospital-acquired 4.04 (1.76–9.44) 0.001  3.51 (1.27–10.12) 0.017 
Escherichia coli      
 AMP–GEN      
  Year of isolation      
   2007–2008 Ref Ref  Ref Ref 
   2009–2010 2.67 (0.63–12.75) 0.194  2.86 (0.66–14.13) 0.174 
   2011–2012 1.23 (0.28–5.86) 0.785  0.95 (0.20–4.75) 0.947 
   2013–2014 2.62 (0.67–11.63) 0.179  2.25 (0.53–10.72) 0.282 
   2015–2016 1.38 (0.33–6.50) 0.665  1.03 (0.22–5.11) 0.975 
  Patient age      
   Nonneonate Ref Ref  Ref Ref 
   Neonate 1.04 (0.42–2.57) 0.924  0.75 (0.27–2.01) 0.568 
  Infection type      
   Community-acquired Ref Ref  Ref Ref 
   Hospital-acquired 2.33 (1.04–5.33) 0.041  2.92 (1.21–7.44) 0.020 
 3GC      
  Year of isolation      
   2007–2008 Ref Ref  Ref Ref 
   2009–2010 3.00 (0.68–16.38) 0.165  4.04 (0.79–26.54) 0.112 
   2011–2012 3.30 (0.74–18.21) 0.134  2.47 (0.45–16.60) 0.319 
   2013–2014 3.43 (0.83–17.83) 0.105  3.07 (0.60–19.99) 0.201 
   2015–2016 3.60 (0.82–19.73) 0.106  2.44 (0.45–16.13) 0.319 
  Patient age      
   Nonneonate Ref Ref  Ref Ref 
   Neonate 0.92 (0.37–2.27) 0.861  0.41 (0.12–1.26) 0.131 
  Infection type      
   Community-acquired Ref Ref  Ref Ref 
   Hospital-acquired 7.50 (3.09–20.01) <0.001  10.14 (3.70–32.14) <0.001 
*3GC, third-generation cephalosporin; AMP–GEN, resistance to both ampicillin and gentamicin; OR, odds ratio; ref, referent. 
†Neonate, 0–28 d of age. 




(aOR 7.30, 95% CI 2.75–22.47) and third-generation 
cephalosporins (aOR 7.50, 95% CI 2.16–35.00) than were 
isolates from nonneonates. Similarly, S. pneumoniae iso-
lates were more likely to be penicillin resistant (aOR 3.87, 
95% CI 1.77–8.83) and Salmonella Typhi isolates more 
likely to be multidrug resistant (aOR 3.16, 95% CI 1.28- 
9.57) among children <5 years of age than among those 
>5 years of age. 
AMR by Site of Infection Acquisition
Approximately four fifths of included isolates were from 
community-acquired infections (1,089, 81.2%) and one 
fifth from hospital-acquired infections (252, 18.8%). In 
almost all instances, the proportion of hospital-acquired 
isolates resistant to a given antimicrobial was higher than 
that of community-acquired isolates (online Technical Ap-
pendix Tables 10–12). K. pneumoniae, the main cause of 
hospital-acquired infections, was >3 times more likely to 
be resistant to ampicillin–gentamicin (aOR 3.62, 95% CI 
1.42–9.58) and third-generation cephalosporins (aOR 3.51, 
95% CI 1.27–10.12) in hospital-acquired isolates (Tables 
3, 4). Increased likelihood of resistance among hospital-
acquired isolates was also found for E. coli ampicillin–gen-
tamicin and third-generation cephalosporin resistance and 
S. aureus methicillin resistance.
Outcomes
We analyzed patient outcomes for 129 admission episodes 
for community-acquired monomicrobial gram-negative 
bacteremia (online Technical Appendix Figure 6). Of these, 
63 (48.8%) isolates were resistant to third-generation ceph-
alosporins and 34 admissions (26.4%) resulted in patient 
death. Isolates consisted of E. coli (48, 37.2%), K. pneu-
moniae (31, 24.0%), A. baumannii (29, 22.5%), and other 
pathogenic Enterobacteriaceae (21, 16.3%). Neonates ac-
counted for 26.4% (34) of the cases; median age was 8.6 
months (interquartile range [IQR] 0.8–29.2 months).
Children from whom third-generation cephalosporin-
resistant bacteria were isolated were less likely than other 
patients to have received appropriate antimicrobial ther-
apy (57% vs. 94%; p<0.001). If appropriate therapy was 
received, it was initiated later for children infected with 
third-generation–resistant than third-generation–sensitive 
organisms (2 days vs. 0 days after admission for those 
who survived [p<0.001]; 0.5 days vs. 0 days for those 
who died [p = 0.004]). Patients who died were younger 
(median age 1.4 vs. 10.2 months; p = 0.002), were more 
likely to have been admitted to an ICU (88% vs. 27%; 
p<0.001), stayed for a shorter time in hospital (3 vs. 8 
days; p<0.001), and were more likely to have been in-
fected with Enterobacteriaceae than A. baumannii (97% 
vs. 71%; p = 0.003) (online Technical Appendix Table 
13). A. baumannii infections were associated with high 
levels of third-generation cephalosporin resistance (90%) 
but a low mortality rate (3%) despite only 48% of patients 
having received appropriate antimicrobials. Conversely, 
Enterobacteriaceae infections were associated with a 
high mortality rate (33%) despite 84% of patients hav-
ing received appropriate antimicrobials (online Technical 
Appendix Table 14).
Multivariable logistic regression (Table 6) showed 
that third-generation cephalosporin resistance was associ-
ated with death (aOR 2.65, 95% CI 1.05–6.96; p = 0.042) 
and ICU admission (aOR 3.17, 95% CI 1.31–8.10; p = 
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Table 4. Logistic regression analysis of resistance trends for the gram-negative Global Antimicrobial Resistance Surveillance  
System pathogen Salmonella enterica serovar Typhi isolated from children at Angkor Hospital for Children, Siem Reap, Cambodia, 
2007–2016* 





OR (95% CI) p value OR (95% CI) p value 
Fluoroquinolone      
 Year of isolation      
  2007–2008 Ref Ref  Ref Ref 
  2009–2010 2.05 (0.47–10.51) 0.345  1.85 (0.42–9.59) 0.422 
  2011–2012 2.97 (0.82–10.37) 0.085  3.05 (0.83–10.74) 0.080 
  2013–2014 4.03  107 (6.26  1045–) 0.992  3.47  107 (9.49  1044–) 0.992 
  2015–2016 4.03  107 (1.11  1043–) 0.992  4.14  107 (6.26  1043–) 0.991 
 Patient age, y      
  >5 Ref Ref  Ref Ref 
  <5 4.48 (0.87–82.12) 0.151  4.57 (0.87–84.30) 0.150 
Multidrug       
 Year of isolation      
  2007–2008 Ref Ref  Ref Ref 
  2009–2010 1.57 (0.56–4.58) 0.395  1.45 (0.50–4.29) 0.491 
  2011–2012 4.32 (1.64–11.44) 0.003  4.55 (1.71–12.17) 0.002 
  2013–2014 2.26 (0.72–7.92) 0.175  2.08 (0.65–7.41) 0.228 
  2015–2016 0.91 (0.33–2.46) 0.850  0.95 (0.34–2.62) 0.927 
 Patient age, y      
  >5  Ref Ref  Ref Ref 
  <5  2.94 (1.22–8.79) 0.029  3.16 (1.28- 9.57) 0.022 
*OR, odds ratio; ref, referent. 
 
 Antimicrobial Resistance in Bacterial Infections
0.013). Multivariable linear regression (online Technical 
Appendix Table 15) controlling for the same variables 
also showed an association between length of hospital 
stay among survivors and third-generation cephalospo-
rin resistance (1.69-fold increase, 95% CI 1.21–2.37). 
Third-generation cephalosporin resistance was associ-
ated with a 2.26-fold increase in hospital costs among 
survivors (95% CI 1.51–3.36) (online Technical Appen-
dix Tables 16, 17). According to this model, the median 
cost per admission would have been US $432.00 (IQR 
$333.30–$613.90) if all infections were third-generation 
cephalosporin sensitive and US $974.10 (IQR $751.60–
$1,384.30) if all infections were third-generation cepha-
losporin resistant.
Discussion
In this hospitalized population of children in Cambodia, 
AMR levels were high, particularly among the gram-nega-
tive GLASS pathogens K. pneumoniae, E. coli, and A. bau-
mannii. These organisms exhibited concerning resistance 
to WHO-recommended first-line sepsis treatment, empha-
sizing the urgent need for revised treatment guidelines (4). 
Few studies inform prevalence estimates of antimicrobial 
resistance in low- and middle-income countries in Asia, 
but compared with what is known, the high levels of gram-
negative resistance reported here are not uncommon (6,16). 
For the gram-positive GLASS pathogens, S. pneumoniae 
resistance was broadly similar to that of the wider region 
(67.7% vs. 59.3% multidrug resistance, respectively) (17). 
Rates of methicillin-resistant S. aureus were comparative-
ly lower; only 40.0% of hospital-acquired isolates were 
methicillin resistant compared with a regional average of 
67.4% (18).
A major strength of this study is the observation of 
resistance trends over an extended period, something rare-
ly possible in low- and middle-income countries because 
of lack of longstanding microbiology services. We found 
heterogeneous trends in resistance over time; resistance 
increased in some organisms (Salmonella Typhi) and de-
creased in others (K. pneumoniae). The most surprising 
temporal trend observed was a drop in the proportion of 
resistant K. pneumoniae isolates for most antimicrobials 
tested, in contrast to largely stable resistance levels in E. 
coli. For K. pneumoniae resistance by site of acquisition, in 
community-acquired isolates, resistance sharply declined 
in 2015–2016, perhaps suggesting loss of a plasmid cod-
ing for multiple resistance determinants. Confirming this 
trend will require a larger dataset from multiple sites in 
Cambodia and further analysis of the underlying resistance 
mechanisms at work using a method such as whole-ge-
nome sequencing. The genetic determinants of resistance 
in colonizing K. pneumoniae and E. coli isolates from 
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Table 5. Logistic regression analysis of resistance trends for the gram-positive Global Antimicrobial Resistance Surveillance System 
pathogens Staphylococcus aureus and Streptococcus pneumoniae isolated from children at Angkor Hospital for Children, Siem Reap, 
Cambodia, 2007–2016* 





OR (95% CI) p value OR ratio (95% CI) p value 
S. aureus      
 Methicillin      
  Year of isolation      
   2007–2008 Ref Ref  Ref Ref 
   2009–2010 0.90 (0.18–4.93) 0.899  1.26 (0.23–7.59) 0.787 
   2011–2012 1.80 (0.47–8.90) 0.418  2.64 (0.62–14.48) 0.215 
   2013–2014 0.59 (0.10–3.42) 0.538  0.66 (0.10–4.19) 0.649 
   2015–2016 1.48 (0.35–7.61) 0.603  1.84 (0.39–10.47) 0.455 
  Patient age†      
   Nonneonate Ref Ref  Ref Ref 
   Neonate 0.18 (0.01–0.88) 0.094  0.14 (0.01–0.75) 0.064 
  Infection type‡      
   Community-acquired Ref Ref  Ref Ref 
   Hospital-acquired 6.21 (2.16–17.43) <0.001  7.80 (2.51–24.81) <0.001 
S. pneumoniae§      
 Penicillin      
  Year of isolation      
   2007–2008 Ref Ref  Ref Ref 
   2009–2010 0.60 (0.12–2.90) 0.525  0.70 (0.13–3.66) 0.669 
   2011–2012 0.52 (0.11–2.28) 0.385  0.42 (0.08–1.95) 0.269 
   2013–2014 0.72 (0.16–3.12) 0.663  0.77 (0.16–3.57) 0.737 
   2015–2016 1.87 (0.38–8.77) 0.424  1.89 (0.36–9.59) 0.436 
  Patient age, y      
   >5  Ref Ref  Ref Ref 
   <5  3.40 (1.63- 7.39) 0.001  3.87 (1.77–8.83) <0.001 
*OR, odds ratio; ref, referent. 
†Ages are grouped into neonate (0–28 d) vs. nonneonate (>29 d) or <5 y vs. >5 y, as appropriate for the organism.  
‡Isolates were defined as hospital-acquired if taken >48 hours after patient admission. 
§Analysis included community-acquired Streptococcus pneumoniae isolates only (n = 160). 
 
SYNOPSIS
this population have been reported elsewhere (CE Moore, 
CM Parry, P Turner, NPJ Day, N Stoesser, unpub data; 
N Stoesser, C Turner, P Turner, BS Cooper, unpub data), 
whereas whole-genome sequencing of invasive isolates is 
ongoing. Loss of antimicrobial selective pressure leading 
to declining resistance may result from changes in national/
regional antimicrobial supply or lack of active drug in an-
timicrobials used (19).
The number of hospital-acquired K. pneumoniae iso-
lates peaked during 2011–2012. This peak may be the result 
of a genuine rise in the rate of hospital-acquired infections 
or the increased rate of blood culture sampling compared 
with previous years. From 2011–2012 onward, the propor-
tion of resistant hospital-acquired K. pneumoniae isolates 
declined. This drop may be linked to maturation of a hos-
pitalwide infection-control program implemented in 2010 
(20) and enforced by prospective hospital-acquired infection 
surveillance from 2015 onward (21) or to the clinical mi-
crobiology service operating since 2012 with a strong focus 
on antimicrobial drug stewardship. Indeed, a recent study 
of prescribing practices at this hospital found 84%–89% of 
antimicrobial drug prescriptions were appropriate (22). The 
apparent success of these interventions suggests that they 
could be useful for combating AMR in similar settings. The 
perceived temporal drop in K. pneumoniae resistance could 
also be attributable to changing proportions of isolates from 
neonates over time; 46%–50% of isolates were from neo-
nates in 2011–2014, dropping to 35% in 2015–2016.
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Figure 1. Antimicrobial resistance time trends, shown as proportion of resistant isolates from community-acquired and hospital-acquired 
infections, by year of isolation, in children at Angkor Hospital for Children, Siem Reap, Cambodia, 2007–2016. A) Klebsiella pneumoniae 
ampicillin–gentamicin resistance; B) K. pneumoniae third-generation cephalosporin resistance; C) K. pneumoniae multidrug resistance; 
D) Escherichia coli ampicillin–gentamicin resistance; E) E. coli third-generation cephalosporin resistance; F) E. coli multidrug resistance; 
G) Salmonella enterica serotype Typhi fluoroquinolone resistance; H) Staphylococcus aureus methicillin resistance; I) Streptococcus 
pneumoniae penicillin resistance. Isolates were defined as hospital-acquired if taken >48 hours after patient admission. Error bars 
indicate 95% CIs.
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This study is unusual in that it directly compares 
different age groups of children, revealing AMR trends 
associated with age. Of note, the dominant pathogen in 
neonates, K. pneumoniae, was also more often resistant 
in neonates. For hospital-acquired isolates, this resistance 
may result from horizontal acquisition of resistant gram-
negative organisms from hospital surfaces, as suggested 
by a recent multicenter study of sepsis in neonates (2). 
Indeed, colonization of neonates by resistant gram-neg-
ative organisms has been shown to be common at Ang-
kor Hospital for Children and associated with subsequent 
invasive infection (23). For community-acquired isolates, 
vertical maternal transfer of resistant organisms may have 
a substantial role and is currently under investigation at 
this center.
Similarly, Salmonella Typhi from children <5 years 
of age was more often multidrug resistant than that from 
those >5 years of age. Isolates from younger children have 
greater genetic diversity (24), although how this diversity 
relates to increased AMR requires further investigation. 
In Cambodia, the most common indication for antimi-
crobial drug use is infections in children <5 years of age; 
thus, children in this age group may be exposed to more 
antimicrobial drugs, leading to greater resistance in organ-
isms causing infection. That S. pneumoniae isolates were 
more often penicillin resistant in children <5 years of age is 
consistent with findings of previous work showing greater 
colonization of this age group by multidrug-resistant pneu-
mococci (25). Vaccination may have a collateral benefit of 
reducing AMR (26), which suggests that it could be useful 
for combating Salmonella Typhi and S. pneumoniae resis-
tance in low- and middle-income countries. Because 85% 
of Salmonella Typhi isolates are simultaneously fluoroqui-
nolone resistant and multidrug resistant, few agents remain 
for treating typhoid in this population, placing even greater 
value on preventive measures such as vaccination. In Janu-
ary 2015, a 13-valent pneumococcal conjugate vaccine was 
introduced in Cambodia (27) with no catch-up campaign, 
meaning that only S. pneumoniae isolates from children 
born in or after December 2014 could have been affected, 
equating to 5 isolates in this dataset. Pneumococcal vacci-
nation is thus unlikely to have had an appreciable effect on 
the AMR trends reported here.
The WHO Global Report on Surveillance identi-
fied a major gap in research comparing resource use in 
resistant versus nonresistant pathogens (28), an area that 
we addressed by demonstrating that resistance is associ-
ated with worse healthcare outcomes, including increased 
deaths and ICU admissions, delayed effective treatment, 
and more than doubled admission costs. Use of patient re-
cords allows these estimates to more closely reflect reality 
than modeled or ecologic analyses, although it is unclear 
whether this increased risk for adverse outcomes repre-
sents greater virulence, delayed treatment, or confounding. 
The observed outcome differences between Enterobacte-
riaceae and A. baumannii infections suggest either a true 
difference in virulence or that a proportion of A. baumannii 
isolates were contaminants, an uncertainty that highlights 
the difficulty of establishing the clinical significance of 
skin-colonizing organisms.
This study has several limitations. The data derive 
from a single nongovernmental hospital for children with 
limited numbers of isolates for some bacterial species; thus, 
trends and outcomes may not be representative of the wid-
er region. The study was retrospective, and classification 
of community-acquired and hospital-acquired infections 
was limited by hospital database and clinical case note 
accuracy, meaning that some community-acquired infec-
tions may have actually been hospital-acquired infections. 
Widespread prehospitalization use of antimicrobials may 
have selected for resistant organisms (29). There were no 
restrictions to blood culture submission over time, but from 
early 2016 onward, clinicians were asked to focus on chil-
dren requiring admission, which may have affected certain 
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Figure 2. Antimicrobial resistance age trends, shown as proportion of resistant isolates from community-acquired and hospital-
acquired infections, by patient age group, in children at Angkor Hospital for Children, Siem Reap, Cambodia, 2007–2016. A) Klebsiella 
pneumoniae third-generation cephalosporin resistance; B) Escherichia coli third-generation cephalosporin resistance; C) Salmonella 
enterica serotype Typhi multidrug resistance; D) Streptococcus pneumoniae penicillin resistance. Ages have been grouped into neonate 
(0–28 d) versus nonneonate (>29 d) or <5 years versus >5 y, as appropriate for the organism. Isolates were defined as hospital-acquired 
if taken >48 hours after admission. Error bars indicate 95% CIs.
SYNOPSIS
organisms (e.g., Salmonella Typhi). Microbiology practice 
variations over time meant that antimicrobial susceptibil-
ity testing was not consistent; however, we believe that 
the value of examining the evidence over a long period 
outweighed the effect that these variations may have had 
on results. For example, in 2009, the Clinical and Labo-
ratory Standards Institute sensitivity zone size cutoffs for 
carbapenems and cephalosporins in Enterobacteriaceae 
increased, which could have resulted in a small number of 
isolates previously classed as sensitive being reclassified as 
resistant. The reported pre-2009 resistance levels are thus 
conservative and would not negate the downward resis-
tance trends observed. In the outcome analysis, we did not 
consider prehospitalization factors, clinical diagnosis, and 
non-HIV/malnutrition co-occurring conditions because 
quantifying those could have introduced substantial report-
ing bias. Furthermore, our cost estimates may be higher 
than actual costs because we did not account for partial/
shared doses and price fluctuations, suggesting that these 
cost estimates are most useful as a relative indication of 
cost burden.
In conclusion, the high rate of AMR in this setting 
of hospitalized children in Cambodia was associated 
with increased deaths and healthcare costs and threatens 
the effectiveness of first-line sepsis treatment. AMR rep-
resents a major threat to children’s health globally (5,6), 
yet there is a dearth of data for children in low-resource 
settings (3–6). By reporting a decade of continuous AMR 
surveillance data, this study fills a gap in the understand-
ing of antimicrobial drug resistance in children in Cam-
bodia. In the context of the current global drive to com-
bat AMR and the goal of the Fleming Fund to improve 
surveillance in low- and middle-income countries, our 
study demonstrates the feasibility and utility of under-
taking accurate long-term antimicrobial drug resistance 
surveillance in these countries. The methods used here are 
reproducible in similar low-resource settings.
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